علاج الميلانوما الأميلانوسيتية مع طفرة BRAF V600 في المرض غير القابل للاستئصال من المرحلة III–IV

References

DOI: 10.1016/j.annonc.2024.11.006

• For BRAF-mutated melanoma, all the options available for BRAF-WT melanoma are still valid, with the addition of combined BRAFi–MEKi therapy if not already used as the immediate prior treatment.
• BRAFi–MEKi therapy after disease progression with first-line immunotherapy should be offered.
• If anti-PD-1-based therapy is not available or patients are considered ineligible for its use, BRAFi–MEKi combination therapy (dabrafenib–trametinib [ESMO-MCBS v1.1 score: 5]; vemurafenib–cobimetinib [ESMO-MCBS v1.1 score: A/5]; binimetinib–encorafenib [ESMO-MCBS v1.1 score: A/5]) is also an option in the first line for patients with BRAF-mutated melanoma [I; A; ESCAT score: I-A].